DBV Technologies SA Sponsored ADR DBVT 深 沪
已收盘 04-02 16:00:00 美东时间
21.06
+0.560
+2.73%
华盛通- 最 高21.3305
- 今 开20.21
- 成交量 44.66万股
- 最 低 19.77
- 昨 收 20.50
- 总市值 12.47亿
- 52周最高 26.185
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 7.00
- 委 比 -73.72%
- 总股本 5920.85万
- 历史最高 505.70
- 量 比 1.51
- 振 幅 7.61%
- 历史最低 3.15
- 每 手 1
- 风险率 5.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多JPMorgan Chase tops 10% stake in DBV Technologies, holds 10.03% voting rights
JPMorgan Chase tops 10% stake in DBV Technologies, holds 10.03% voting rights JPMorgan Chase crossed above 10% stake in DBV Technologies on March 18, 2026. Holding totaled 27,912,104 shares, equal to 10.03% of share capital and voting rights. Disclosure cited an increase in shares held by assimilati
04-02 17:14
美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
Alphabet To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, visit our analyst ratings page.
03-27 21:47
Guggenheim Reiterates Buy on DBV Technologies, Maintains $51 Price Target
Guggenheim analyst Yatin Suneja reiterates DBV Technologies (NASDAQ:DBVT) with a Buy and maintains $51 price target.
03-27 20:45
DBV Technologies GAAP EPS of -$1.05
DBV Technologies press release (DBVT): FY GAAP EPS of -$1.05. On December 31, 2025, DBV held $194.2 million in cash and cash equivalents compared to $32.5 million of cash and cash equivalents on Decem...
03-27 17:16
DBV Technologies Q4 EPS $(0.23) Beats $(0.63) Estimate, Sales $645.000K Miss $655.000K Estimate
DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.63) by 63.49 percent. This is a 4.55 percent decrease over losses of $(0.22) per share from
03-27 05:48
DBV Technologies Reports Full Year 2025 Financial Results and Business Update
<p>DBV Technologies reported its 2025 financial results and business updates. The company advanced its VIASKIN® Peanut Patch clinical programs for peanut-allergic toddlers and children, bolstered its executive leadership, and held $194 million in cash as of December 2025, with additional $94 million received in January 2026, funding into Q2 2027. The company achieved positive topline results from the Phase 3 VITESSE trial in 4-7 year-olds and ini...
03-26 21:06
Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Dow futures down 0.2%. Hesai Group -ADR shares drop 6.6% after reporting lower quarterly earnings and sales. Other stocks also down in pre-market.
03-24 20:02
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
DBV Technologies highlighted positive results from its Phase 3 VITESSE study for the VIASKIN® Peanut Patch, showing significant improvement in peanut-allergic children. Approximately 83% of treated children increased their eliciting dose at month 12, compared to 48% in the placebo group. The treatment demonstrated a statistically significant effect, with 46.6% of children meeting responder criteria, compared to 14.8% in the placebo group. The pat...
02-28 19:25
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
DBV Technologies' CEO, Daniel Tassé, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit on February 12, 2026, at 2:30pm ET in New York. The session will be live streamed and available for replay on the company’s investor website for 90 days. DBV, a late-stage biopharmaceutical company, is developing treatments for food allergies using its VIASKIN® patch technology. For more information, visit their w...
02-09 21:30
